According to data published in Tumor Discovery.

Approximately 10 % of patients result from families with multiple cases of pancreatic cancer. There is significant reason to believe this clustering was because of genetics, but we had not, to this point, been able to get the causative genes that explained the cluster of pancreatic malignancy for most these families, said business lead writer Alison Klein, Ph.D., associate professor of oncology at the Sidney Kimmel In depth Cancer Center at Johns Hopkins and director of the National Familial Pancreas Tumor Registry. Co-workers and Klein used next-generation sequencing, including whole genome and entire exome analyses, and determined ATM gene mutations in two kindreds with familial pancreatic cancers. When these initial findings were examined in a large series for individuals, ATM mutations were within four of 166 subjects with pancreatic malignancy but had been absent in 190 spousal control subsets..

Agilent Technologies launhces handheld FTIR spectrometer Agilent Systems Inc. today introduced a next-generation cellular spectroscopy product that’s ideal for on-site tests in a broad selection of applications, including advanced materials, art, historical items, geology, agriculture, composites, coatings and polymers. Thirty-five % lighter than its predecessor, the 4300 FTIR supplies the performance, mobility, flexibility and user comfort never before attained in a handheld FTIR device. ‘We believe this handheld FTIR is a game-changer for the cellular FTIR field,’ stated Phil Binns, Agilent's vice president and managing director of Spectroscopy.